Presentation Material
FY2025
FY2025
Financial results for FY2025
- FY2025 Second Quarter Results Briefing Session -Movie-
- FY2025 Second Quarter Results Briefing Session - Material (1.6 MB)
- FY2025 First Quarter Results Conference Call - Script (1.5 MB)
- FY2025 First Quarter Results Conference Call - Material (1.2 MB)
- FY2025 Third Quarter Results Briefing Session - Script (1.7 MB)
- FY2025 Third Quarter Results Briefing Session - Material (1.3 MB)
- FY2025 Second Quarter Results Briefing Session - Script (1.5 MB)
Other Material
- Briefing Session Movie on the Agreement with Italfarmaco
- Briefing Session Script on the Agreement with Italfarmaco (2.2 MB)
- Briefing Session Material on the Agreement with Italfarmaco (686.3 KB)
- Information on the 44th J.P. Morgan Healthcare Conference Now Available (122.3 KB)
- The 44th J.P.Morgan Healthcare Conference Presentation materials (2.4 MB)
FY2024
FY2024
Financial results for FY2024
- [Updated] FY2024 Results Briefing Session - Material (1.4 MB)
- FY2024 Results Briefing Session - Movie
- FY2024 Results Briefing Session - Script (2.7 MB)
- [Updated] FY2024 Third Quarter Results Conference Call - Script (1.0 MB)
- [Updated] FY2024 Third Quarter Results Conference Call - Material (684.6 KB)
- FY2024 Second Quarter Results Briefing Session -Script- (2.1 MB)
- FY2024 Second Quarter Results Briefing Session -Movie-
- FY2024 Second Quarter Results Briefing Session Material (1.4 MB)
- FY2024 First Quarter Results Conference Call -Script- (1.6 MB)
- FY2024 First Quarter Results Conference Call (869.1 KB)
Other Material
FY2023
FY2023
Financial results for FY2023
- FY2023 Results Briefing Session -Script- (2.3 MB)
- FY2023 Results Briefing Session -Movie-
- FY2023 Results Briefing Session -Material- (1.2 MB)
- [Updated] Appendix to the Consolidated Financial Summary FY2023 (Flash report) (1.1 MB)
- Appendix to the Consolidated Financial Summary FY2023 3rd Quarter (897.2 KB)
- FY2023 First-Half Results Briefing Session -Script- (4.1 MB)
- FY2023 First-Half Results Briefing Session -Movie-
- FY2023 First-Half Results Briefing Session -Material- (2.2 MB)
- Appendix to the Consolidated Financial Summary FY2023 First-Half (726.1 KB)
FY2022
FY2022
Financial results for FY2022
- FY2022 Second-Half Results Briefing Session -Movie-
- FY2022 Second-Half Results Briefing Session -Financial Results - (962.6 KB)
- FY2022 Second-Half Results Briefing Session -Script- (8.2 MB)
- FY2022 Second-Half Results Briefing Session - Business Highlights - (2.1 MB)
- FY2022 First-Half Results Briefing Session -Movie-
- FY2022 First-Half Results Briefing Session -Script- (4.0 MB)
FY2021
FY2021
Financial results for FY2021
- FY2021 Second-Half Results Briefing Session Q&A -Script- (322.9 KB)
- FY2021 Second-Half Results Briefing Session -Script- (3.7 MB)
- FY2021 Second-Half Results Briefing Session - Business Highlights - (1.6 MB)
- FY2021 Second-Half Results Briefing Session - Financial Results - (898.5 KB)
- FY2021 First-Half Results Briefing Session - Research and Development - (3.4 MB)
- FY2021 First-Half Results Briefing Session - Financial Results - (1.4 MB)
- FY2021 First-Half Results Briefing Session -Script- (4.5 MB)
Other Material
- WORLDSymposium2021 Poster: A Comparison of Developmental Trajectories in Sibling Cases with Neuropathic MPS-II Receiving Conventional and Novel Enzyme Replacement Therapies (989.1 KB)
- WORLDSymposium2021 Poster: Therapy for Mucopolysaccharidosis Type II with an Intravenous Blood-Brain Barrier-Crossing Enzyme (JR-141): Phase III Global Clinical Trial Design (474.5 KB)
- WORLDSymposium2021 Poster:Exploration of the Efficacy of Pabinafusp-alfa (JR-141) on Neurocognitive Development in Hunter Syndrome (MPS-II): 52-week Data from Clinical Trials in Japan and Brazil (721.4 KB)
- WORLDSymposium2021 Poster: Drug Delivery across the Blood-Brain Barrier and Resultant Reduction of Heparan Sulfate in the Cerebrospinal Fluid in the Patients with Hunter Syndrome (MPS-II): An Integrated Analysis of 25-Week Japanese and Brazilian Data on P (1.3 MB)
- WORLDSymposium2021 Poster: Reduction of Heparan Sulfate in the Brain by Pabinafusp Alfa Results in Prevention of Neurodegeneration and Neurocognitive Impairment in a Mouse Model of Mucopolysaccharidosis II (1.1 MB)
- WORLDSymposium2021 Poster: Phase I/II Clinical Trial Design for a Novel Therapy for Mucopolysaccharidosis Type I with an Intravenously Administered Blood-Brain Barrier-Crossing Enzyme (JR-171) (578.3 KB)
- WORLDSymposium2021 Poster: Usefulness of Hexose Tetrasaccharide as a Biomarker for Monitoring Glycogen Accumulation in Peripheral Tissues and Brain in Pompe Disease (380.2 KB)
- WORLDSympoisum2021 Poster: Non-Clinical Evaluation of a Blood-Brain Barrier-Penetrable N-Sulfoglucosamine Sulfohydrolase in a Mouse Model of Mucopolysaccharidosis IIIA (1.2 MB)
- WORLDSymposium2021 Poster: Non-Clinical Evaluation of a Blood-Brain Barrier-Penetrable α-N-Sulfoglucosamine Sulfohydrolase in a Mouse Model of Mucopolysaccharidosis IIIB (1.1 MB)
FY2020
FY2020
Financial results for FY2020
- FY2020 Results Briefing Session - Script - (4.6 MB)
- FY2020 Results Briefing Session - Research and Development Highlights - (4.6 MB)
- FY2020 Results Briefing Session - Financial Results - (2.0 MB)
- FY2020 First-Half Results Briefing Session - Script - (3.7 MB)
- FY2020 First-Half Results Briefing Session - Research and Development - (2.6 MB)
- FY2020 First-Half Results Briefing Session - Financial Results - (1.2 MB)
FY2019
FY2019
Financial results for FY2019
- FY2019 Results Briefing Session - Script - (4.9 MB)
- FY2019 Results Briefing Session - Midterm Plan - (3.9 MB)
- FY2019 Results Briefing Session - Research and Development Highlights - (1.3 MB)
- FY2019 Results Briefing Session - Financial Results - (850.4 KB)
- FY2019 First-Half Results Briefing Session - Research and Development - (1.8 MB)
- FY2019 First-Half Results Briefing Session - Financial Results - (825.1 KB)
- FY2019 First-Half Results Briefing Session - Script - (2.8 MB)